The vaccine is manufactured at Valneva’s leading vaccine production site in Livingston, Scotland. The approval is based on IXCHIQ ® ’s final pivotal Phase 3 data, published in The Lancet, which ...
The approval is based on IXCHIQ ® 's final pivotal Phase 3 data, published in The Lancet , which included more than 4,000 participants and demonstrated that a single dose of the live-attenuated ...
Valneva Receives Marketing Authorization in the UK for the World's First Chikungunya Vaccine, IXCHIQ
The approval is based on IXCHIQ ® 's final pivotal Phase 3 data, published in The Lancet, which included more than 4,000 participants and demonstrated that a single dose of the live-attenuated ...
Valneva has received Medicines and Healthcare products Regulatory Agency (MHRA) authorisation in the UK for the world’s first - and only - Chikungunya vaccine, IXCHIQ. The single-dose vaccine is ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 February 2025, approved the vaccine chikungunya vaccine (live) (brand name IXCHIQ) to protect adults against chikungunya ...
Merck & Co’s – known as MSD outside the US and Canada – adult-specific 21-valent pneumococcal conjugate vaccine has been recommended for approval by the European Medicines Agency’s human medicines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback